Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 184   

Articles published

AZN 4,709.69 -1.31 (-0.03%)
price chart
2 Numbers That Could Make AstraZeneca plc A Terrific Turnaround Play
But regardless of whether you fancy stashing the cash with AstraZeneca, I strongly urge you to check out THIS BRAND NEW AND EXCLUSIVE REPORT which reveals the seven key steps you need to take to become a stock market millionaire.
Related articles »  
Neil Woodford Praises AstraZeneca plc's Prospects
Respected fund manager Neil Woodford has come out to praise the potential of AstraZeneca (LSE: AZN) (NYSE: AZN.US) this morning, after the company updated investors on its progress over the past few months.
Why Pfizer Inc. (PFE) May Not Bid For AstraZeneca plc (ADR) (AZN) Again?
Pfizer's main objective behind AstraZeneca plc (ADR) (NYSE:AZN) was to gain access to its cancer drugs pipeline. However, failure pushed Pfizer to look for alternatives.
Related articles »  
AstraZeneca plc: Why $4.20 Is The Magic Number
Executive compensation plans have always drawn shareholders criticism but AstraZeneca's (LSE: AZN) (NYSE: AZN.US) 'Azip' plan has been designed with shareholders in mind.
Related articles »  
At What Price Would AstraZeneca plc Be A Bargain Buy?
Finally, if you already have AstraZeneca tucked away in your portfolio and are in the market for more great blue-chip shares, I recommend you help yourself to this FREE Motley Fool report.
Report: Pfizer 'Unlikely' To Pursue Acquisition Of AstraZeneca  Benzinga
Related articles »  
Can AstraZeneca plc Beat The FTSE 100 In 2015?
Just one year ago, AstraZeneca's (LSE: AZN) (NYSE: AZN.US) share price was generally tracking the index and sentiment in the stock remained rather subdued.
AstraZeneca plc Earns Hold Rating from Berenberg Bank (AZN)  WKRB News
Credit Suisse (CS) Reaffirms Neutral Rating For AstraZeneca (AZN)  Bidness ETC
Related articles »  
AstraZeneca Bets Long Term on Cancer Drugs
LONDON´┐Ż AstraZeneca PLC is betting on new cancer drugs to help drive long-term revenue growth as the British group stakes out an independent future after the rejection of Pfizer Inc. 's $120 billion takeover offer in May.
AstraZeneca share price: Neil Woodford upbeat on pharma company's ...  iNVEZZ
Pfizer Cancer Pact With Merck Shows Waning Astra Pursuit  Businessweek
Related articles »  
My Top 3 Pharmaceutical Stocks For 2015: GlaxoSmithKline plc, AstraZeneca ...
Investing in BTG, AstraZeneca and GlaxoSmithKline could prove to be a great move for 2015, and I think that all three companies could post excellent returns over the next year.
AstraZeneca plc Lifts Full-Year Guidance In Third-Quarter Results
The key takeaway from today's results is that AstraZeneca has lifted its full-year top and bottom line revenue guidance for the second consecutive quarter.
AstraZeneca plc (ADR) (AZN) Posts Upbeat 3Q Earnings, Raises Full-Year ...  Bidness ETC
AstraZeneca Raises Forecast on Lack of Nexium Competitor  Bloomberg
Related articles »  
AstraZeneca plc And GlaxoSmithKline plc Are Strong Buys, But For Very ...
AstraZeneca's steady recovery continues apace, according to recent Q3 results, with both revenues and earnings at the higher end of expectations.